Dual Agonism Explained: Why Tirzepatide Targets Two Receptors

A receptor agonist is a molecule that binds to a specific receptor and activates its signalling function. A dual agonist activates two distinct receptors. In tirzepatide's case, these are the GIP receptor and the GLP-1 receptor. Each receptor, when activated, triggers its own intracellular signalling cascade and produces specific physiological effects. By activating both simultaneously, tirzepatide engages multiple metabolic pathways that would normally require two separate medications.

Dual agonism differs from polypharmacy (using multiple drugs) in that a single molecule delivers all the pharmacological activity. This unified approach can simplify treatment regimens, potentially improve medication adherence, and create synergistic metabolic effects that neither receptor alone could achieve.

GLP-1 and GIP are both incretin hormones—natural gut peptides released in response to nutrient intake. Historically, GLP-1 was considered the dominant incretin because early research showed GLP-1 receptor agonists were metabolically effective. GIP was thought to play a secondary role and was sometimes studied in a negative light. However, more recent research revealed that GIP contributes substantially to postprandial insulin secretion and appetite regulation, and that it has largely glucose-dependent properties.

By targeting both receptors, tirzepatide exploits complementary physiological effects. GLP-1 activation promotes insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces hunger. GIP activation similarly enhances insulin secretion in a glucose-dependent manner but also modulates other metabolic pathways. Together, these dual effects create a broader metabolic intervention than GLP-1 alone.

Both GIP and GLP-1 receptors share some overlapping effects: they both enhance glucose-stimulated insulin secretion, suppress glucagon release, and slow gastric emptying. However, they also activate some distinct pathways. GLP-1 receptors are expressed more prominently in certain brain regions associated with appetite control, while GIP receptors may contribute more substantially to energy expenditure and lipid metabolism in some tissues. Additionally, GIP has been linked to modulation of inflammatory responses, though this is an area of active research.

The redundancy in some effects provides robustness—if one pathway is less responsive in a particular individual, the other may compensate. The distinct effects allow synergistic activity in metabolic outcome measures like weight loss and glycaemic control. This combination appears to explain why tirzepatide outperforms single-agonist peptides in clinical trials.

Single-receptor agonists like semaglutide (GLP-1 only) and liraglutide (GLP-1 only) have demonstrated significant metabolic benefits. However, their efficacy is capped by the maximum effect achievable through one receptor pathway. Even at the highest tolerated doses, they cannot activate GIP signalling. Tirzepatide's dual activation allows additional metabolic intervention through the GIP pathway, potentially explaining superior weight loss and glycaemic improvements observed in head-to-head trials.

Furthermore, dual agonism may provide a more physiologically complete intervention. Endogenous GIP and GLP-1 are released together postprandially, suggesting evolution has optimised metabolic regulation using both hormones in concert. Tirzepatide mimics this natural pairing more closely than single agonists.

The SURMOUNT and SURPASS trial programs directly compared tirzepatide (dual agonist) against semaglutide (GLP-1 only) and other agents. In weight management (SURMOUNT), tirzepatide achieved numerically greater weight loss than semaglutide at comparable doses. In type 2 diabetes (SURPASS), tirzepatide demonstrated superior HbA1c reduction compared to other GLP-1 agonists and basal insulin. These outcomes suggest dual agonism translates to measurable clinical advantages.

Mechanistic studies using receptor occupancy measurements have shown that tirzepatide achieves substantial occupancy of both GIP and GLP-1 receptors at therapeutic doses. This dual occupancy correlates with the magnitude of metabolic improvement observed clinically.

While dual agonism has demonstrated clinical benefit, the precise degree to which each receptor contributes to the overall metabolic effect remains incompletely quantified in humans. Experimental approaches such as selective antagonists or genetic models can help partition effects, but human trials specifically designed to dissect GIP versus GLP-1 contributions are limited. Future research may employ receptor occupancy imaging or selective blockade studies.

Additionally, whether dual agonism provides benefits beyond weight loss and glycaemic control—such as improved cardiovascular outcomes or reduced mortality—is an ongoing area of investigation. SURPASS trials have been extended for longer-term follow-up, which will provide more complete safety and efficacy data.